


**Clinical Commissioning
Policy: Pre-implantation
Genetic Diagnosis (PGD)**

April 2013

Reference: NHSCB/E01/P/a



NHS Commissioning Board

Clinical Commissioning Policy: Pre-implantation Genetic Diagnosis (PGD)

First published: April 2013

**Prepared by the NHS Commissioning Board Clinical Reference Group for
Genetics**

© Crown copyright 2013

First published April 2013

Published by the NHS Commissioning Board, in electronic format only.

Contents

Policy Statement	4
Equality Statement	4
Plain Language Summary	4
1. Introduction	5
2. Definitions	6
3. Aim and objectives	6
4. Criteria for commissioning	7
5. Patient pathway	9
6. Governance arrangements	9
7. Epidemiology and needs assessment	10
8. Evidence base	14
9. Rationale behind the policy statement	20
10. Mechanism for funding	20
11. Audit requirements	20
12. Documents which have informed this policy	21
13. Links to other policies	21
14. Date of review	22
15. Glossary of terms	22
References	23
Appendix 1: Indications for PGD in the South East England area	28
Appendix 2: PGD service providers by NHS CB Regions	38

Policy Statement

The NHS Commissioning Board (NHS CB) will commission three cycles of Pre-implantation Genetic Diagnosis (PGD) for couples who have, or are carriers of, a proven genetic disorder and who wish to avoid the birth of an affected child, in accordance with the criteria outlined in this document.

In creating this policy the NHS CB has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement

The NHS CB has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. The NHS CB is committed to ensuring equality of access and non-discrimination, irrespective of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex (gender) or sexual orientation. In carrying out its functions, the NHS CB will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which they are responsible, including policy development, review and implementation.

Plain Language Summary

Pre-implantation genetic testing is a technique used in reproductive medicine to identify genetic defects in embryos created through in vitro fertilisation (IVF). Pre-implantation genetic diagnosis (PGD) can be offered when one or both genetic parents have, or are carriers of, a known genetic abnormality; testing is performed on their embryos to determine whether the embryo is at risk of genetic disease.

This commissioning policy has been produced in order to provide and ensure equity, consistency and clarity in the commissioning of PGD services in England.

Information on the outcome of treatments for these patients will be collected and considered when this policy is reviewed.

1. Introduction

Pre-implantation genetic testing is a technique used in reproductive medicine to identify genetic defects in embryos created through in vitro fertilisation (IVF). Pre-implantation genetic diagnosis (PGD) can be offered when one or both genetic parents have, or are carriers of, a known genetic abnormality; testing is performed on their embryos to determine whether the embryo is at risk of genetic disease.

The use of PGD enables couples at risk of passing on an inherited disorder to significantly decrease the risk of having an affected child. Couples known to be at risk of transmitting genetic disorders to their children have various options with regard to reproductive decision making. These are:

- To remain childless
- To adopt a child
- To pursue gamete donation – (this process involves assisted conception techniques in which one or both parents would not be the biological parent of the child);
- To conceive naturally, and accept the risk of their child inheriting the genetic condition (this might include recurrent miscarriages of non-viable pregnancies as a result of the genetic condition)
- To conceive naturally and undergo prenatal diagnosis (PND) post conception. The two commonly used post conception diagnostic procedures are amniocentesis and chorionic villus sampling (CVS). If the fetus is found to have the genetic condition of concern, the parents then have to decide whether or not to opt for termination of the pregnancy (TOP)
- To undergo PGD.

PGD represents the only way for parents to have an unaffected child to whom they are both biological parents, without risking the need for termination of pregnancy. Whilst PGD is one of the reproductive options for couples at risk of passing on a genetic condition, the fact that the technology requires a highly skilled technical team and laboratory set up means it is significantly more expensive than the more common PND option. A very limited number of providers deliver the service within a regulated environment. PGD forms a small part of all Assisted Reproduction Technologies; in the UK, PGD forms 0.4% of all ART procedures.

The aim of a PGD service is to allow couples at significant risk of having a child with a genetic disorder, who would not consider termination of an affected pregnancy, to have a child that is genetically related to them and at very low risk of being affected. Previous commissioning arrangements led to inconsistent policies on access to PGD across the country.

This commissioning policy has been produced in order to provide and ensure equity, consistency and clarity in the commissioning of PGD services in England.

2. Definitions

Pre-implantation genetic diagnosis (PGD) is a technique that involves testing cell(s) from embryos created outside the body by IVF for a genetic disorder. Tests are carried out for the specific disorder that the embryos are known to be at significant risk of inheriting. Unaffected embryos are selected for transfer to the uterus in the hope that a normal birth will ensue.

PGD offers couples (who are usually fertile) the opportunity of having a healthy child of their own, whilst avoiding having to undergo a termination of an affected foetus detected through PND. For some people, termination of pregnancy is either unacceptable or less preferable.

Patients who meet the access criteria outlined in this policy are entitled to receive three complete cycles of PGD.

Whilst the pre-implantation testing process may be used for other indications, its primary use under consideration in this policy is to significantly decrease the risk of having a child affected by the serious genetic condition the parents either have, or are at risk of passing on.

Completed PGD cycle with IVF/ICSI - ovarian stimulation, egg recovery, fertilisation, embryo biopsy, genetic testing and single fresh embryo transfer. This includes the provision for future transfers of single frozen embryos where the initial procedure does not result in a viable embryo and the subsequent storage of embryos. Frozen embryos must be transferred within ten years of the initial treatment cycle (HFEA guidance).

Abandoned PGD cycle with IVF/ICSI - Prior to egg retrieval, usually due to lack of response (where less than 3 mature follicles are present) or excessive response to gonadotrophins; failure of fertilisation; failure of cleavage of embryos and failure to produce any unaffected embryos.

3. Aim and objectives

Aim

This policy document aims to specify the conditions under which PGD will be routinely commissioned by the NHS CB as a means of making it possible for couples at significant risk of having a child with a genetic disorder to have a child that is genetically related to them and at very low risk of being affected.

Objectives

- To reduce the variation in access to PGD
- To ensure that PGD is commissioned for those conditions for which there is acceptable evidence of clinical benefit and cost-effectiveness
- To reduce unacceptable variation in clinical practice in the conditions referred for PGD
- To promote the cost-effective use of healthcare resources

4. Criteria for commissioning

Mandatory Criteria for the Couple

- The couple should be at risk of having a child with a serious genetic condition.
- The couple should have been referred to the PGD provider by an NHS Clinical Genetics Service
- The risk of conceiving a pregnancy affected by a serious genetic condition should be 10% or more
- The couple should have received genetic counselling from a clinical geneticist or a registered genetic counsellor.
- The female partner should be under 40 years of age at the time of treatment
- The female partner should have a BMI of more than 19 and less than 30.
- Both partners should be non smokers
- There should be no living unaffected child from the current relationship.
- The HFEA must have licensed the indication for PGD.
- The test must be included in the list of UKGTN approved tests, or suitable for inclusion.
- The couple should not be seeking PGD primarily because they are infertile.

Couples meeting the above criteria will be eligible to receive three (3) complete cycles of IVF/ICSI in conjunction with PGD. Couples who have previously self funded will be entitled to NHS treatment to reach the three (3) completed cycles. Where couples have previously self funded an IVF cycle in conjunction with PGD and frozen embryos exist, then they must utilise the previously frozen embryos first, before undergoing ovarian stimulation, egg retrieval and fertilisation again if the frozen embryo does not lead to a pregnancy.

Policy Exclusions

The following uses of the PGD technology are excluded from this policy.

- Non medical gender selection e.g. for the purpose of family balancing. This is illegal in the United Kingdom (UK).¹
- Human Leucocyte Antigen (HLA) typing to produce a donor sibling for a child requiring an allogeneic stem cell transplant.² This is still considered experimental³ and will be governed by the NHS CB research policy.
- Using PGD to address infertility or to prevent miscarriages of unknown aetiology.⁴
- Pre-implantation Genetic Screening (PGS). Here, genetic testing is used to screen embryos for various abnormalities in chromosomes typically the number of chromosomes (chromosomal aneuploidies).⁵

PGD versus PGS

PGD should NOT be confused with Pre-implantation Genetic Screening (PGS) mentioned above. The widespread use of PGS without evidence of its ability to improve delivery rates has been reported as a problem in the field of IVF.⁶

In PGS, no specific genetic diagnosis is tested for. The parents are presumed to be chromosomally normal and the test is used to look for abnormalities in chromosome numbers. The main indications suggested for PGS are advanced maternal age (usually defined as maternal age over 37 or 38 years), repeated implantation failure (usually defined as three or more failed embryo transfer procedures involving high-quality embryos), repeated miscarriage (RM) in patients with normal karyotypes (usually at least three previous miscarriages) and severe male factor infertility.⁷

Since 2004⁸ there have been 11 randomised controlled trials (RCTs), mainly for advanced maternal age, which have shown no benefit of performing PGS. In a systematic review and meta-analysis of the RCTs for PGS, the authors have reported there is no evidence of a beneficial effect of PGS as currently applied on the live birth rate after IVF. On the contrary, for women of advanced maternal age PGS significantly lowers the live birth rate from 26% after IVF without PGS, to between 13% and 23% using PGS.⁹

In the absence of evidence of its clinical and cost effectiveness, there is no intention to support the introduction of PGS into NHS clinical practice.

5. Patient pathway

Patients requiring PGD should be referred first to their Regional Clinical Genetics Service. Patients will be referred from a Clinical Genetics Service to a licensed PGD provider, where an initial outpatient appointment (a screening appointment) will be arranged to discuss whether a PGD might be possible and also to assess the couple's suitability for treatment.

Both the clinical genetics service and the PGD provider will be required to ensure the patient meets the criteria for accessing the PGD service. Once it has been agreed that the couple meet the criteria, and the couple after a discussion of their reproductive options choose PGD as an option to pursue, three cycles of treatment will be offered with a full review after each cycle.

If it is decided after an unsuccessful cycle, that the treatment is unlikely to benefit the couple, further treatment should not be offered.

6. Governance arrangements

The NHS CB expects robust mechanisms will be put in place to support clinical governance to comply with the HFEA Code of Practice. For example:

1. The centre must have a valid HFEA licence which includes the provision of PGD, and abide by the HFEA regulations for PGD testing. There are currently 18 licensed PGD service providers in England as listed in appendix 1. The HFEA provides details of these PGD clinics online.¹⁰ Commissioners will only purchase PGD services from PGD providers who have been licensed by the HFEA. The NHS CB will monitor the inspection reports provided by the HFEA and will discuss the findings with the providers where appropriate.
2. The laboratory where the test is being carried out must have Clinical Pathology Accreditation (CPA).
3. There must be an existing licence to carry out that test from the HFEA or the PGD clinic must apply for and receive a licence prior to treatment if that condition is not currently licensed.

In addition to the approval of the HFEA, clinics must make their own judgement about whether PGD is appropriate treatment for a particular couple, using guidance contained in the HFEA's Code of Practice.

7. Epidemiology and needs assessment

Epidemiology

An epidemiological description of the more than 200 conditions currently licensed by the HFEA for PGD use is not practical.

Referrals for PGD

At present information on patients who have been referred for PGD is not recorded. However information from Guy's Hospital in London, indicates about a quarter of the patients (25%) referred for PGD, proceed to treatment after they have been provided with information about the process, chance of success, outcomes and alternatives.¹¹ The Centre for Reproductive Health in London, reports a PGD take up rate of 50%.¹²

Utilisation of PGD

When couples opt to take up PGD, an application for funding is made on their behalf to commissioners by PGD providers after they have been assessed as meeting the existing commissioning criteria. There is currently no information on this for the most of the country, but the London SCG maintained a database of such requests since 2003 for South East England covering London, South East Coast in NHS South of England and East of England in NHS Midlands and the East.

Data from South East England shows a general increase in the request for funding PGD cycles as shown in table 1 below. Whilst the request for funding PGD cycles shows some general fluctuations there was a clear significant increase in the requests for funding PGD cycles in the last year 2011/2012. In the first three months of 2012/13, this increased demand for funding PGD cycles PGD funding compared with previous years has continued.

Table 1: No of requests of funding for PGD by SCG area by year

Year	East of England	London	South East Coast	South East England total
Oct 2003 to Mar 2005	1	16	3	20
05/06	12	35	8	55
06/07	11	20	6	37
07/08	10	40	7	57
08/09	11	30	9	50
09/10	14	42	16	72
10/11	19	38	12	69
11/12	31	79	22	132

Regional Variation in demand for PGD funding

Data from South East England shows there is regional variation in the demand for funding PGD cycles with the highest rate of demand for funding recorded in the London area.

Table 2: Regional variations in PGD demand profile

Year	Average no of requests per million population (2005 – 2012)	No of requests per million population for 2011/2012
East of England	1.8	5.4
London	3.7	10.1
South East Coast	1.8	5.1
South East England area	2.7	7.4

Indications for demand for funding PGD cycles

Across South East England, demand for funding PGD cycles follows international trends with the top five requests being PGD for:

- Structural Chromosomal abnormalities (translocations)
- Sickle Cell Disease
- Cystic Fibrosis
- Huntington's Disease
- Duchenne Muscular Dystrophy

In recent years, there has been an increase in the number of requests of PGD for Cancer susceptibility conditions such as for BRCA 1/2, Hereditary Non Polyposis Colorectal Cancer, Retinoblastoma, Neurofibromatosis, Familial Adenomatous Polyposis, von Hippel Lindau and Hereditary Diffuse Stomach cancer. A complete outline of the indications for which PGD has been requested for is presented in Appendix 1.

Utilisation of PGD – (NHS and Privately funded PGD cycles)

Data from the HFEA on the number of PGD cycles that took place shows a steady increase in the utilisation of the PGD technology as evidenced by the number of PGD cycles taking place. There is considerable year on year fluctuations in the level of increase as shown in the table below. Between 2004 and 2010 there was a 293% increase in the number of PGD cycles carried out. Assuming that the international flow of patients is minimal and all the PGD cycles were for UK residents, this puts the utilisation rate at 6.0 per million population for the UK in 2010, compared to a utilisation rate of 8.6 per million population in South East England for 2010/11.

Table 3: No of PGD cycles in UK from 2004 - 2010

Calendar Year	No of PGD cycles carried out	%age increase in cycles from previous year	PGD cycles per million UK population
2004	95		1.6
2005	134	41%	2.2
2006	184	37%	3.0
2007	198	8%	3.2
2008	214	8%	3.5
2009	288	35%	4.7
2010	373	30%	6.0

Source of information: HFEA annual reports

Population Information from ONS

Overall, there is evidence that indicates demand for PGD is highest in South East England with the London population having a significantly higher demand than the rest of the country.

Potential Need

Using the incidence and prevalence of the top 20 indications for which PGD has been requested in South East England (which together have accounted for 95% of the total requests), an estimated 5000 couples could be eligible for PGD every year.¹³ However, these couples, who could be regarded as having a need, (PGD will be a reproductive option) may for various reasons not necessarily choose to proceed with PGD treatment. Evidence from the literature and practice indicates that whilst natural conception and PND was the most common reproductive choice for many of these couples in the past, PGD is increasingly being seen as a first choice. The profile of couples who choose PGD generally shows couples from these four main categories:

- Couples at high risk of having a child affected by a genetically-caused disease or malformation;
- Couples at high genetic risk who have undergone “conventional” prenatal diagnosis and who did terminate recurrent pregnancies after an affected foetus was found;
- Couples at risk of giving birth to a child affected by a genetically-caused disease or malformation and who object to termination of pregnancy.
- Couples who have an affected child.

Published literature indicates that when PGD costs are met by public funding or mandated insurance coverage, demand for PGD steadily increases. Belgium introduced full reimbursement of all ART including PGD in 2003 and currently has PGD utilisation rates of about 28 per million population.^a France¹⁴ also has a fully public funded PGD programme and reported a 15% increase in utilisation rates between 2007 and 2008. In the USA, states with mandated insurance cover have PGD utilisation rates twice that of states without mandated insurance cover. It is therefore anticipated that PGD utilisation rates for England will increase with implementation of this policy.

^a Reported rate for Belgium is 33 per million population. However, their local report indicates 15% of their PGD activity is for foreigners. Thus the utilisation rate for local population is calculated as 28 per million population.

8. Evidence base

The effectiveness of PGD in reducing the reproductive risk by successfully identifying and only transferring healthy embryos

The aim of PGD technology is to ensure the embryo transferred is free from the genetic condition for which the test is applied. Information about the effectiveness of PGD in reducing the risk of passing on a genetic disease compared with a couple getting pregnant spontaneously is based on observational studies, with the largest case series being that from the European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium.^{15, 16} In its most recent report, information is provided on over 10,000 PGD cycles that took place between January 1997 and December 2008.¹⁷

The two main techniques used in the PGD process to identify embryos at risk of the genetic disease being tested for are the Polymerase Chain Reaction (PCR) and Fluorescence in situ hybridisation (FISH). If these tests wrongly identify an affected embryo as normal and the embryo results in an affected pregnancy, the false negative test is generally termed a misdiagnosis.¹⁸

The cumulative number following PGD performed between 1997 and 2008 have been reported in the ESHRE case series as about 0.2%. i.e. about 2 in a 1000 as shown in table 4 below.

Table 4: Misdiagnosis reported in the ESHRE 1997 - 2008 data

Indication	No of PGD cycles that proceeded to embryo transfer	No of misdiagnosis reported to ESHRE consortium	% misdiagnosis
Chromosomal abnormalities	2731	3	0.11%
Single Gene Disorders	3727	10	0.27%
Sexing only for X-linked disease	880	4	0.45%
Overall PGD	7338	17	0.23%

Twelve of these false negatives were after PCR testing and the remaining three (3) after FISH testing. The majority of the misdiagnosis for PCR testing (9/12)

occurred prior to 2001 and was mainly in single gene disorders. PCR assays have since become increasingly technically advanced. In the last three years for which data is available i.e. 2006 – 2008, no PCR misdiagnoses have been reported in the 3424 PGD cycles for single gene disorders carried out in this time.

The 4 misdiagnosis reported for X-linked disorders happened a time when PCR was used to determine the diagnosis. FISH technology has now superseded the older PCR technology for sexing since 2005. For the most recent data available, ESHRE series X¹⁹ and XI²⁰, again no misdiagnosis is reported.

In summary, the evidence indicates the incidence of misdiagnosis after PGD is very low.

The effectiveness of PGD in producing a live birth

The most recent ESHRE data reports²¹ that out of 2235 PGD cycles that went on to oocyte retrieval, there were 413 deliveries. The live birth rate of 18.4% for the most recent data year reflects the findings in a large study of 2753 unselected consecutive cycles carried out 1498 couples in Belgium²² and reported a live birth rate of 17% per cycle.

The 2008 UK data from the HFEA reports a higher live birth rate after PGD of 26.9%. There were significant differences in the live birth outcome depending on the age of the patient as shown in table 5.

Table 5: Live birth rate for pre-implantation genetic diagnosis cycles, United Kingdom, 2008

Age of woman (years)	Live births/cycle (number)	PGD Live birth rate (%) [*]	IVF live birth rate (%)
Less than 35	28/92	30.4	33.1
35 to 37	17/53	32.1	27.2
38 to 39	6/33	-	19.3
40 to 42	1/12	-	12.5
43 to 44	0/2	-	4.9
Over 44	0/1	-	2.5
<i>Total</i>	52/193	26.9	25.4

Source: HFEA annual report. <http://www.hfea.gov.uk/>

1. See also <http://www.hfea.gov.uk/ivf-success-rate.html>

^{*} Live birth rate as % not provided when the number of cycles are less than 50, as per HFEA.

Some individual PGD centres report higher live birth rates for PGD as shown in table 6 below. The rates shown do not take into consideration the number of twin pregnancies (which is not regarded as a good outcome following ICF or PGD because of the increased risk of antenatal and neonatal complications).

Table 6: Live birth rates for PGD cycles in 2010 - UK

Region and Clinic Name	Fresh PGD cycles	No of live births	Live Births rate
Care Nottingham	26	9	35%
Assisted Reproduction & Gynaecology Centre (Wimpole Street)	5	0	0%
The Bridge Centre	15	3	20%
The Centre for Reproductive & Genetic Health (University College Hospital)	56	23	41%
Guy's Hospital	160	58	36%
IVF Hammersmith	7	2	29%
The London Fertility Clinic	1	0	0%
Oxford Fertility Unit	3	0	0%
Edinburgh ACU	3	1	33%
Glasgow Royal Infirmary	16	3	19%
Total	292	99	35%

In summary, the live birth rate after PGD is similar to that after IVF. Some individual PGD providers report higher live birth rates.

The cost-effectiveness of the PGD technology

A single study²³ in the United States has assessed whether the use of PGD for carrier couples of cystic fibrosis to prevent the birth of a child with cystic fibrosis represents a cost savings to society.

A Markov model was applied to couples in which both partners were cystic fibrosis carriers. The authors calculated the net benefit of giving birth to a child as the present value of lifetime earnings minus lifetime medical costs. The annual

average medical costs for cystic fibrosis reported in this USA study was \$20,331 (£12,918^b).

The authors report the net benefit of PGD over normal conception for PGD in a woman age less than 35 years is \$182,000 (£115,631). For women aged 35 – 40 years, the net benefit was \$114,000 (£72,431.36). There was no benefit for women over 40. The net benefit varied with age, the maximum number of PGD cycles, whether or not couples were “allowed” to conceive naturally whilst undergoing PGD and if the outcome was a twin delivery.

The authors conclude PGD provides a cost savings to society when used by carrier couples of cystic fibrosis and recommend PGD should be offered for the prevention of an affected child.

The model is only relevant to PGD for cystic fibrosis. The main limitation in generalising this study to the setting in England is that the costs reported in the study and the lifetime earnings in England would differ significantly. Also nearly all the higher benefit from PGD reported is shown in the sensitivity analysis to be based on the higher probability of healthy twins with a consequent high lifetime earnings. Valuing twins the same as singletons reduced the net benefit of PGD in women under 35 years to \$1,800 (£1,143).


In summary, there is a significant gap in the literature on the cost effectiveness of PGD for even the most common indications.

Limits to the PGD treatment cycles

In a prospective observational study of PGD in 1498 couples, Verpoest et al²⁴ report the observed cumulative delivery rates depended on the age of the patient and increased consistently for the first three cycles then levelled off after the third cycle as shown in figure 4.1.

^b Currency convertor - \$1=£0.635335
<http://www.xe.com/ucc/convert/?Amount=182000&From=USD&To=GBP>

Figure 1: Observed cumulative delivery rates post PGD by age groups



In summary, there is some evidence that delivery rates consistently improve with the first three cycles of PGD.

BMI >30

Being overweight or obese is associated with decreased pregnancy rates, increased requirement for gonadotrophins and a higher miscarriage rate. An elevated BMI is also associated with increased technical difficulty during egg collection and an increased obstetric risk. Obesity decreases successful pregnancy rates in both natural and assisted conception cycles, with fertility being partially restored if weight loss can be achieved.^{25, 26, 27}

Smoking

Smoking has in various studies been reported to be associated with lower fertility rates, result in adverse obstetrical outcomes including spontaneous abortion²⁸, placenta praevia^{29, 30}, placental abruption³¹, preterm birth³², stillbirth³³, fetal growth restriction³⁴, low birth weight^{35, 36}, sudden infant death syndrome³⁷ and a higher risk of IVF failures.^{38, 39}

Age: The female partner should be under 40 years of age at the time of treatment

In addition to the natural decline in fertility with age⁴⁰, increasing maternal age has been shown to be one of the major factors that affect the outcome of IVF⁴¹ and

PGD⁴² cycles Studies reporting the outcome of IVF show the cumulative live birth rate significantly decreases with increasing maternal age. Stern et al.⁴³ have reported the cumulative live-birth rate after three cycles was 60.1% for ages <35 years and declined steadily to 8.5% for ages ≥43 years. Similar findings have been reported more recently⁴⁴ in a large review of assisted reproduction cycles. By the third cycle, the conservative and optimal estimates of live-birth rates with autologous oocytes had declined from 63.3% and 74.6%, respectively, for women younger than 31 years of age to 18.6% and 27.8% for those 41 or 42 years of age and to 6.6% and 11.3% for those 43 years of age or older.

In summary, the evidence indicates a BMI >30, Smoking and age > 39 decreases the chances of a successful ART cycle.

Resource Implications of this policy

There is likely to be a significant extra resource implication if this policy is implemented but also potentially a reduction in the long term cost of caring for affected individuals. Current PGD cycles cost NHS commissioners between £8,000 and £12,500 with an average cost of £11,000 for the 1st cycle and £10,000 for subsequent cycles.

An anticipated increase in the utilisation of PGD, if access is made more equitable, and a significant cost price increase by one of the PGD providers are likely to result in a significant cost pressure. However failing to adopt a national policy would also have major cost implications.

To get an idea of the resource implication, the impact in South East England is presented in table 7 below. The following assumptions are made:

1. The calculation for **existing** funding in South East England assumes PCTs funded 90% of the requests for PGD funding they received and that each couple had two complete cycles at an average cost of £9,000 per cycle.
2. The calculation for the existing funding in the whole of England assumes all the cycles reported to the HFEA were for English patients, and the total number of cycles funded in 2011 was 500 as a result of a 35% increase in the numbers from 2010.

Whilst it is anticipated that implementation of the policy will lead to an increase in the utilisation rates, the calculations are based on the NHS CB proposing to fund a maximum of 500 PGD cycles in the first two years of this policy. This takes into consideration existing capacity in PGD providers. In future years, it should be possible to model utilisation of the service better as detailed information from the whole of England will be available to commissioners.

- 35% of couples have a live birth after the first cycle.
- 30% of couples who are not successful after the first cycle decide not to proceed with a second cycle.
- The live birth rate after the second cycle is 35% and after that cycle, another

30% of couples who were not successful decline a third cycle.

- The average cost for a first cycle in 2013/14 is estimated to be £11,000 and the cost of subsequent cycles £10,000.

Table 7: Resource Implication of PGD policy for South East England

	Existing funding in PCT budgets	Year 1	Year 2
London	£900,194	£1,363,685	£1,500,053
South East Coast	£232,308	£351,919	£387,110
East of England	£338,783	£513,215	£564,536
England	£4,452,570	£7,331,638	£8,064,801

9. Rationale behind the policy statement

The scientific evidence shows that PGD is technically feasible for an increasing number of genetic conditions and reduces the reproductive risk.

10. Mechanism for funding

Through the relevant area team.

11. Audit requirements

There is currently no central database to which PGD service providers report on NHS activity. As part of this commissioning policy, PGD Service providers will provide two sets of auditable data to the NHS commissioners for all the NHS PGD cycles they have provided:

Data set 1: Monthly minimum data set on the PGD cycles for that month

Data set 2: An annual report and dataset on all patients who were referred to the PGD provider – whether they decided against PGD or went on to have treatment. This annual report should provide information on the desired primary outcome of

PGD which is the birth of an unaffected baby. In addition to the live birth rates, reports should also cover secondary indicators such as

- Multiple Births
- Prematurity and low birth weight
- Method of Delivery
- Misdiagnosis
- Other complications
- Acceptance of the procedures

The data fields to be reported on will be outlined in the information schedule of the Service Specification.

The data and reports would not only enable monitoring of this PGD policy but would also enable outcome information to be collected and collated to inform future PGD policy needs.

12. Documents which have informed this policy

This document has been informed by:

- The Yorkshire and Humber PGD policy⁴⁹
- The London SCG PGD Clinical Advisory Group PGD Access Criteria⁵⁰
- Pre-implantation Genetic Diagnosis – A comprehensive Healthcare Needs Assessment for South East England⁵¹
- The Department of Health PGD – Guiding Principles for Commissioners of NHS Services September 2002⁵²

13. Links to other policies

This policy is based on the existing Yorkshire and Humber PGD policy. Whilst the PGD technology requires IVF and ICSI services, the policy is NOT linked to the IVF policies of the Clinical Commissioning Groups. As previously stated, IVF and ICSI are used as part of the PGD process. They are not being used to treat existing infertility.

14. Date of review

April 2014

15. Glossary of terms

Term	Meaning
amniocentesis	A test that can be carried out during pregnancy to determine whether the foetus has a specific problem. It is conducted by taking and analysing a sample of amniotic fluid.
Blastocytes	Any undifferentiated embryonic cell (Lawrence, 2000: 75)
Chorionic villus sampling (CVS)	This is a test for serious foetal problems. It is available to pregnant women, particularly those with a family history of inherited disorders, or who are over 35. It's an alternative to amniocentesis (where a sample of the mother's amniotic fluid is taken for testing). CVS has the advantage that it can be done earlier than amniocentesis, at about 10 weeks after fertilisation. (NHS Direct b, 2009).
Chromosomal Abnormality	An abnormality with one or more chromosomes, or in the number of chromosomes.
chromosome	A structure within cells that contains genetic information.
Cleavage stage embryos	This is when the fertilised cell has started to divide.
Congenital malformations	A malformation of the developing foetus. In this case it refers to those caused by genetic/chromosomal abnormalities.
Embryo	A fertilised egg.
Foetus	The unborn child after the end of the eighth week of pregnancy to the moment of birth.(NSC, 2009)
Gonadotrophins	Hormones that stimulate the function of the organs in which reproductive cells are produced (Lawrence, 2000; 254)
Human Fertilisation and Embryology Authority (HFEA).	UK's independent regulator overseeing the use of gametes and embryos in fertility treatment and research. (HFEA, c, 2009)

Term	Meaning
In Vitro Fertilisation (IVF)	This is a process whereby eggs are removed from the ovaries and fertilised with sperm in the laboratory. It is utilised in the PGD process in order for the fertilised eggs (embryo's) to be tested for a specific genetic abnormality, with an unaffected embryo subsequently being placed in the woman's womb. (HFEA, 2009).
Intra-cytoplasmic Sperm Injection	This is a technique that can be used in IVF whereby a sperm is injected into the egg to assist in fertilisation. (NHS Direct, 2009).
Oocyte	A not yet fully developed egg cell.
Ovarian Stimulation	A technique used in IVF to assist in egg retrieval.
Pre natal diagnosis	Determining if a foetus has a specific problem, by performing a clinical test.
Pronucleate embryo	Embryo whereby two nuclei (the part of the cell that contains the DNA) from the sperm and the egg are present. (These subsequently fuse together).
The UK Genetic Testing Network (UKGTN)	This advises the NHS on genetic testing across the whole of the UK. It aims to ensure the provision of high quality equitable genetic testing services. (UKGTN A, 2009)

References

1. HFEA Code of Practice. 8th Edition.
<http://www.hfea.gov.uk/code.html?rnd=53806935998631643875311> Accessed August 2011.
2. Samuel GN, Strong KA, Kerridge I, Jordens CF, Ankeny RA, Shaw PJ. Establishing the role of pre-implantation genetic diagnosis with human leucocyte antigen typing: what place do "saviour siblings" have in pediatrics transplantation? Arch Dis Child. 2009;94(4):317–20.
3. London SCG PGC panel terms of reference.
4. Franssen M, Musters A, van der Veen F, Repping S, Leschot N, Bossuyt P, Goddijn M, Korevaar J. Reproductive outcome after PGD in couples with recurrent miscarriage carrying a structural chromosome abnormality: a systematic review. Human Reproduction Update, 2011;17(4):467 – 475.
5. Basille C, Frydman R, El Aly A, Hesters L, Fanchin R, Tachdjian G et al. Preimplantation Genetic Diagnosis: State of the Art. Eur J Obstet Gynecol Reprod Biol. 2009;145(1):9-13.

6. Braude P, Flinter F. Use and misuse of Preimplantation genetic testing. *BMJ* 2007; 335; 752 – 754.
7. Harper J, Coonen E, De Rycke M, Fiorentino F, Geraedts J, Goossens V, Harton G, Moutou C, Pehlivan Budak T, Renwick P, Sengupta S, Traeger-Synodinos J, Vesela K. What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium Steering Committee. *Hum Reprod.* 2010;25(4):821-3. Epub 2010 Feb 2.
8. Harper J, Coonen E, De Rycke M, Fiorentino F, Geraedts J, Goossens V, Harton G, Moutou C, Pehlivan Budak T, Renwick P, Sengupta S, Traeger-Synodinos J, Vesela K. What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium Steering Committee. *Hum Reprod.* 2010;25(4):821-3. Epub 2010 Feb 2.
9. S. Mastenbroek, M. Twisk, F. van der Veen, and S. Repping. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs *Hum. Reprod. Update* 2011;17(4):454-466. first published online April 29, 2011.
10. HFEA website <http://guide.hfea.gov.uk/guide/>
11. Lashwood A. Personal communication. January 2012.
12. Grant E. Personal Communication. January 2012.
13. Addei DJ. A Comprehensive health care needs assessment for PGD in South East England.
14. Di Costanzo S, Lvy P, Thpot F, Shojaei T. PGD activity in France: the French Specificities. *Reproductive BioMedicine Online.* 2010 20(S1);pS40.
15. Harper J, Wilton L, Traeger-Synodinos, Goossens V Moutou C SenGupta S et al. The ESHRE PGD Consortium: 10 years of data ollection
16. *Human Reproduction Update*, 2012;18(3):234-47.
17. Harper J, Coonen E et al. ESHRE PGD consortium data collection X: cycles from January to December 2007 with pregnancy follow-up to October 2008 *Human Reproduction*, 2010;25(11):2685 – 2707.
18. Goossens V, Traeger-Synodinos J, Coonen E, De Rycke M, Moutou C, Pehlivan T, Derks-Smeets IA, Harton G. ESHRE PGD Consortium data collection XI: cycles from January to December 2008 with pregnancy follow-up to October 2009 *Hum Reprod.* 2012;27(7):1887-911.
19. Wilton L, Thornhill A, Traeger-Synodinos J, et al. The causes of misdiagnosis and adverse outcomes in PGD. *Hum. Reprod* 2009;24(5):1221-1229.

20. Harper J, Wilton L, Traeger-Synodinos, Goossens V, Moutou C, SenGupta S et al. The ESHRE PGD Consortium: 10 years of data collection. *Human Reproduction Update*, 2012;18(3):234-47.
21. Goossens V, Traeger-Synodinos J, Coonen E, De Rycke M, Moutou C, Pehlivan T, Derks-Smeets IA, Harton G. ESHRE PGD Consortium data collection XI: cycles from January to December 2008 with pregnancy follow-up to October 2009 *Hum Reprod*. 2012;27(7):1887-911.
22. Goossens V, Traeger-Synodinos J, Coonen E, De Rycke M, Moutou C, Pehlivan T, Derks-Smeets I, Harton G. ESHRE PGD Consortium data collection XI: cycles from January to December 2008 with pregnancy follow-up to October 2009 *Hum Reprod*. 2012;27(7):1887-911.
23. Verpoest W, Haentjens P, De Rycke M, Staessen C, Sermon K, Bonduelle M et al. Cumulative Reproductive Outcome after preimplantation genetic diagnosis: a report on 1498 couples. *Hum. Reprod*, 2009;24(11):2951-2959.
24. Davis L, Champion S, Fair S, Baker V, Garber A. A cost-benefit analysis of Preimplantation genetic diagnosis for carrier couples of cystic fibrosis. *Fertility and Sterility*, 2010;93:1793 – 1804.
25. Verpoest W, Haentjens P, De Rycke M, Staessen C, Sermon K, Bonduelle M et al. Cumulative Reproductive Outcome after preimplantation genetic diagnosis: a report on 1498 couples. *Hum. Reprod*, 2009;24(11):2951-2959.
26. Maheshwaria, Stoffberg L, and Bhattacharya S. Effect of overweight and obesity on assisted reproductive technology – a systematic review, *Human Reproduction Update* 2007;13(5):433 – 444.
27. Norman J. The Adverse effects of Obesity on Reproduction. *Reproduction* 2010;140:343-345.
28. Balen AH, Anderson RA; Policy & Practice Committee of the British Fertility Society Impact of obesity on female reproductive health: British Fertility Society, Policy and Practice Guidelines. *Hum Fertil (Camb)*. 2007;10(4):195-206.
29. George L, Granath F, Johansson AL, Anneren G, Cnattingius S. Environmental tobacco smoke and risk of spontaneous abortion. *Epidemiology* 2006;17:500-505.
30. Hung TH, Hsieh CC, Hsu JJ, Chiu TH, Lo LM, Hsieh TT. Risk factors for placenta previa in an Asian population. *Int. J. Gynaecol. Obstet*. 2007;97:26-30.
31. Chelmow D, Andrew DE, Baker ER. Maternal cigarette smoking and placenta previa. *Obstet. Gynecol*. 1996;87:703-706.
32. Ananth CV, Smulian JC, Vintzileos AM. Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: a meta-analysis of observational studies. *Obstet. Gynecol*. 1999;93:622-628.

33. Fantuzzi G, Aggazzotti G, Righi E, Facchinetti F, Bertucci E, Kanitz S, Barbone F, Sansebastiano G, Battaglia MA, Leoni V, et al. Preterm delivery and exposure to active and passive smoking during pregnancy: a case-control study from Italy. *Paediatr. Perinat. Epidemiol.* 2007;21:194-200.
34. Hogberg L, Cnattingius S. The influence of maternal smoking habits on the risk of subsequent stillbirth: is there a causal relation? *BJOG* 2007;114:699-704.
35. Hammoud AO, Bujold E, Sorokin Y, Schild C, Krapp M, Baumann P. Smoking in pregnancy revisited: Findings from a large population-based study. *Am. J. Obstet. Gynecol.* 2005;192:1856-1862. discussion 1862–1863.
36. Bernstein IM, Mongeon JA, Badger GJ, Solomon L, Heil SH, Higgins ST. Maternal smoking and its association with birth weight. *Obstet. Gynecol.* 2005;106:986-991.
37. Jaddoe VW, Troe EJ, Hofman A, Mackenbach JP, Moll HA, Steegers EA, Witteman JC. Active and passive maternal smoking during pregnancy and the risks of low birthweight and preterm birth: the Generation R Study. *Paediatr. Perinat. Epidemiol.* 2008;22:162-171.
38. Mitchell EA, Milerad J. Smoking and the sudden infant death syndrome. *Rev. Environ. Health* 2006;21:81-103.
39. Augood C, Duckitt K Templeton A. Smoking and female infertility: a systematic review and meta-analysis. *Human Reproduction*, 1998;13(6): 1532-1539.
40. Dechanet C, Anahory T, Mathieu D J, Quantin X, Reyftmann L, Hamamah S, Hedon B, Dechaud H. Effect of Cigarette smoking on Reproduction. *Human Reproduction Update*, 2011;17(1):76-95.
41. Fukuda J, Kumagai J, Kodama H, Murata M, Kawamura K, Tanaka T. Upper limit of the number of IVT=ET treatment cycles in different age groups, predicted by cumulative take home baby rate. *Acta Obstet Gynecol Scand* 2001;80:71 – 3.
42. Moragianni VA, Penzias AS..Cumulative live-birth rates after assisted reproductive technology. *Curr Opin Obstet Gynecol.* 2010;22(3):189-92.
43. Davis L, Champion S, Fair S, Baker V Garber A. A cost-benefit analysis of Preimplantation genetic diagnosis for carrier couples of cystic fibrosis. *Fertility and Sterility*, 2010;93:1793 – 1804.
44. Stern JE, Brown MB, Luke B, Wantman E, Lederman A, Missmer SA, Hornstein MD. Calculating cumulative live-birth rates from linked cycles of assisted reproductive technology (ART): data from the Massachusetts SART CORS. *Fertil Steril.* 2010;94(4):1334-40.

45. Luke B, Brown MB, Wantman E, Lederman A, Gibbons W, Schattman GL, Lobo RA, Leach RE, Stern JE. Cumulative birth rates with linked assisted reproductive technology cycles. N Engl J Med.2012;28;366(26):2483-91.
46. Newsweek Feb 4 2012
<http://www.thedailybeast.com/newsweek/2010/02/04/what-is-a-life-worth.html>
47. Lifetime costs <http://www.phgfoundation.org/news/633/>
48. <http://www.mda.org.au/media/accesslaunch/ExecutiveSummary5.pdf>
49. <http://www.hdsa.org/images/content/1/4/14499.pdf>
50. Yorkshire and Humber Specialised Commissioning Group PGD Policy 19/11
<http://www.yhscg.nhs.uk/commissioning/treatment-policy.htm> . Accessed 1st March 2012.
51. PGD Clinical Advisory panel of South East England Genetic Consortium (London Specialised Commissioning Group) Terms of reference document
52. Addei D. Preimplantation Genetic Diagnosis. A comprehensive healthcare needs assessment.
53. Department of Health PGD – Guiding Principles for Commissioners of NHS services September 2002
54. Trust page on HFEA website. Available from
<http://guide.hfea.gov.uk/guide/SearchResults.aspx> Accessed 116/07/2012.

Appendix 1: Indications for PGD in the South East England area

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Translocation	6	27	9	11	13	30	16	35	147
Sickle Cell Disease	2	2	5	14	7	6	4	12	51
Cystic Fibrosis		2	3	5	3	9	8	14	44
Huntington's Disease	1	6	2	5	6	8	6	7	41
Duchenne Muscular Dystrophy		2	3	5	1	3	4	5	23
B Thalassaemia	3	4	2	3	2	1	1	5	21
Myotonic Dystrophy			5	3	4	2	1	3	18
Spinal Muscular	3	6	1	1	1	2	3		17

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Atrophy									
Fragile X				1	2	2	2	4	11
BRCA 1/2			1	1			5	4	11
Retinoblastoma	1	2		2				3	8
Haemophilia				1	1	2	1	1	6
Neurofibromatosis type 1 (NF1)					2		1	2	5
X-linked Adrenoleucodystrophy		2	1				1	1	5
Becker MD		1		1	2				4
Hereditary Non Polyposis Colorectal					1	1		2	4

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
cancer (HNPCC)									
Familial Adenomatous Polyposis (FAP)			1				1	1	3
Herlitz Junctional Epidermolysis Bullosa (HJ EB)				2	1				3
Von Hippel Lindau (VHL)	1				1			1	3
Alport's Syndrome	1					1			2
Crouzon Syndrome							1	1	2
Cystinosis			1				1		2
Fabrys Disease							2		2

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Facioscapulohumeral muscular dystrophy (FSHMD)					1			1	2
Hereditary diffuse stomach cancer					1		1		2
Hunter syndrome type 11								2	2
Marfan Syndrome								2	2
Tay Sachs						1	1		2
X Linked					1	1			2
X linked Pelizaeus Merzbacher Disease			1	1					2
X linked sensory Neuropathy (Charcot								2	2

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Marie Tooth)									
Alpers Syndrome								1	1
ARPKD							1		1
Ataxia Telangiectasia (AT)							1		1
Barth	1								1
Cerebral Cavernous Malformations (CCM)							1		1
Chronic Granulomatous Disease	1								1
Congenital Core Myopathy (RYR1)								1	1

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Congenital Diaphragmatic Hernia						1			1
Cystic Fibrosis + Haemophilia A				1					1
De Novo Saethre-Chotzen								1	1
Deafness								1	1
Dentatorubral-pallidoluysian atrophy (DRPLA)								1	1
Early onset familial Alzheimer disease								1	1
Emery-Dreifuss Muscular Dystrophy								1	1

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Fraser Syndrome								1	1
Gaucher's disease								1	1
Krabbe's Disease							1		1
Non ketotic hyperglycinaemia							1		1
Oculopharyngeal muscular dystrophy (OPMD)							1		1
Osteogenesis Imperfecta type 1A								1	1
Paracentric Inversion of Chromosome 3 and pericentric inversion of chromosome 6								1	1

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Paraganglioma							1		1
Pyridoxine Dependent Epilepsy						1			1
Recurrent Hydatidiform Molar Pregnancies								1	1
Recessive Dystrophic Epidermolysis Bullosa							1		1
Senior Loken Syndrome								1	1
Severe Hypospadias						1			1
Simpson-Golabi- Behmel Syndrome								1	1

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
Spinal muscular atrophy & Familial Haemophagocytic Lymphohistiocytosis								1	1
Stickler Syndrome								1	1
Stomach Cancer predisposition (CDH1 mutation)								1	1
Supravalvular Aortic Stenosis (SVAS)								1	1
Treacher Collins Syndrome								1	1
Turner Syndrome							1		1
X linked agammaglobulinaemia			1						1

Indication for PGD	Oct 03- Mar 05	2005/2006	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012	Grand Total
X linked Anderson Fabry								1	1
X linked L1 syndrome								1	1
X linked lymphoproliferative disease (XLP)								1	1
X linked Severe Combined Immunodeficiency Disorder								1	1
X linked wiscott-aldrige syndrome			1						1
X-linked Ichthyosis		1							1
Xlinked retinitis pigmentosa								1	1
Total	20	55	37	57	50	72	69	132	492

Appendix 2: PGD service providers by NHS CB Regions

Region and Clinic Name	PGD cycles in 2010 ⁵³	Private/ NHS
PGD providers in the Northern Region (Covering North East, North West and Yorkshire and Humber areas)		
Newcastle Fertility Centre	0	NHS & Private
Care Manchester	0	Private
Care Sheffield	0	NHS & Private
Sheffield Teaching Hosp	0	NHS & Private
PGD providers in the Midlands and East Region – Covering East Midlands, West Midlands and East of England areas)		
Care Northampton	0	NHS & Private
Care Nottingham	27	NHS & Private
Birmingham Women's	0	NHS & Private
London		
Assisted Reproduction & Gynaecology Centre (Wimpole Street)	5	Private
The Bridge Centre	15	NHS & Private
The Centre for Reproductive & Genetic Health (University College Hospital)	61	NHS & Private
CRM London	0	NHS & Private
Assisted conception Unit Guy's Hospital	199	NHS & Private
IVF Hammersmith	7	NHS & Private
The Lister Clinic	0	Private
The London Fertility Clinic	2	NHS & Private

Region and Clinic Name	PGD cycles in 2010⁵³	Private/ NHS
London's Women Clinic (Harley Street)	0	NHS & Private
Reproductive Genetics Institute	0	Private only
PGD providers in the South (Covering South West, South Central and South East Coast areas)		
Oxford Fertility Clinic	0	NHS & Private

In Scotland, there are three (3) HFEA licensed PGD providers.